These data suggest that CLK2 deficiency or treatment with the CLK2 inhibitor TG003 can promote IMQ-induced inflammatory lesions in vivo, indicating that CLK2 may be a therapeutic target for inflammatory diseases and that inhibiting CLK2 may be a strategy to cure viral infection. The gene discussed is CLK2; the disease is viral infectious disease.